Dicerna Pharmaceuticals, Inc.
DRNA
DRNA was delisted on the 27th of December, 2021.
98 hedge funds and large institutions have $901M invested in Dicerna Pharmaceuticals, Inc. in 2019 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 32 increasing their positions, 28 reducing their positions, and 16 closing their positions.
14% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 28
13% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 16
4% more capital invested
Capital invested by funds: $867M → $901M (+$34.4M)
0% more funds holding
Funds holding: 98 → 98 (0)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$8.64M |
| 2 |
UONDDL
University of Notre Dame du Lac
South Bend,
Indiana
|
+$7.06M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$5.53M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$4.28M |
| 5 |
Nuveen
Charlotte,
North Carolina
|
+$3.45M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$21.8M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$19.8M |
| 3 |
BM
Bridger Management
New York
|
-$8.19M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$6.09M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$4.5M |
DRNA Hedge Fund Activity: Q2 2019 in Review
98 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Dicerna Pharmaceuticals, Inc. (DRNA) for Q2 2019, worth a combined $901M — up 4% from $867M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new DRNA positions and 16 closed out — a net gain of 2 holders — while 32 added to existing stakes and 28 trimmed.
The largest buyer was Millennium Management, adding an estimated $8.64M. The largest seller was Bain Capital Life Sciences Investors, cutting an estimated $21.8M.
- 98 institutional investors held Dicerna Pharmaceuticals, Inc. (DRNA) as of Q2 2019, unchanged from Q1 2019.
- Funds reported $901M of Dicerna Pharmaceuticals, Inc. stock for Q2 2019, up 4% quarter-over-quarter.
- 18 funds opened new Dicerna Pharmaceuticals, Inc. positions in Q2 2019 and 16 closed out, a net change of +2 holders.
- The largest Dicerna Pharmaceuticals, Inc. buyer in Q2 2019 was Millennium Management, an estimated $8.64M added.
- The largest Dicerna Pharmaceuticals, Inc. seller in Q2 2019 was Bain Capital Life Sciences Investors, an estimated $21.8M sold.
Based on aggregated 13F filings for Q2 2019.